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Background: Published reports showed trends for increased risk of in-hospital mortality, short-term mortality and rehospitalization rates in 
patients admitted for acute decompensated heart failure (ADHF) that discontinued β-blockers, however a comprehensive analysis has not 
been conducted.
methods: Relevant studies from January of 2000 through December of 2013 were identified in the MEDLINE, EMBASE and COCHRANE 
electronic databases. Where appropriate data were available, weighted odds ratios were estimated using random effects meta-analysis 
techniques.
results: Five observational studies and one randomized clinical trial (n=2704 patients who continued β-blocker therapy and n=439 patients 
who discontinued β-blocker therapy) that reported the short-term effects of β-blocker withdrawal in ADHF were included in the analyses. In 
two studies, β-blocker withdrawal significantly increased risk of in-hospital mortality (odds ratio [OR]: 3.73 [95% Confidence Interval (CI): 
1.51-9.19)]. Short-term mortality (OR 1.71 [95% CI: 1.09-2.68]; 4 studies), and combined short-term re-hospitalization and/or death (OR 
2.16 [95% CI: 1.01-4.61]; 4 studies) were also significantly increased.
conclusion:  Discontinuation of β-blockers in patients admitted with ADHF was associated with significantly increased in-hospital mortality, 
short-term mortality, and the combined end-point of short-term rehospitalization and/or mortality rates. These data suggest β-blockers 
should be continued in all ADHF patients if their clinical picture allows.
